Study of Pulmonary Rehabilitation In Nintedanib Treated Patients With IPF: Improvements in Activity, Exercise Endurance Time, and QoL
Phase of Trial: Phase IV
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 15 Oct 2019 Planned End Date changed from 19 Nov 2020 to 19 May 2022.
- 15 Oct 2019 Planned primary completion date changed from 19 Nov 2020 to 19 May 2022.
- 19 Nov 2018 Status changed from not yet recruiting to recruiting.